Investigation of poor predictive factors in extensive stage small cell lung cancer under etoposide‐platinum‐atezolizumab treatment

BACKGROUND: The phase III trial IMpower133 showed that platinum and etoposide plus atezolizumab was associated with improved overall survival (OS) and progression free‐survival (PFS) when compared to the placebo group in treatment‐naïve extensive stage (ES) small cell lung cancer (SCLC). Due to supe...

Descripción completa

Detalles Bibliográficos
Autores principales: Lim, Jeong Uk, Kang, Hye Seon, Shin, Ah. Young, Yeo, Chang Dong, Kim, Sung Kyoung, Kim, Jin Woo, Kim, Seung Joon, Lee, Sang Haak
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9715810/
https://www.ncbi.nlm.nih.gov/pubmed/36274214
http://dx.doi.org/10.1111/1759-7714.14697

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9715810/
https://www.ncbi.nlm.nih.gov/pubmed/36274214
http://dx.doi.org/10.1111/1759-7714.14697

Ejemplares similares